NCT01022801View on ClinicalTrials.gov

A Phase II Dose Response Study in Japan in Chronic Hepatitis B

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Chronic Hepatitis B
Interventions
DRUG

Entecavir

Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY